Clinical Trials Logo
  1. Home
  2. Lymphoma, Extranodal NK-T-Cell
  3. NCT03439501

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Lymphoma, Extranodal NK-T-Cell Clinical Trial

Official title:
A Phase II Study of Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Clinical Trial Summary

This study was conducted to evaluate the complete response rate of avelumab in patients with NK / T-cell lymphoma besides relapsed or refractory stage lymphoma.

Clinical Trial Description

Extranodal natural killer/T-cell lymphoma (ENKTL) generally has poorer prognosis than other lymphomas because the majority of patients are present as advanced disease and show poor response to treatment. In particular, treatment of relapsed or refractory stage ENKTL is very poor and there is no standard treatment. ENKTL is entirely infected with Epstein-Barr virus (EBV) and the prevalence of this disease is closely related to EBV. Therefore, the biological properties of ENKTL may be affected by EBV-related protein and LMP1 may induce activation of molecules in various sub-channels, such as PI3K/Akt and NF-kB, and affect the aggressiveness of lymphoma. As an increase in PDL1 has been reported recently among the major roles of LMP1, the role of Immuno-oncology drug targeting PDL1 among ENKTL is expected. Therefore, Avelumab that inhibits PDL1 may effectively treat NK/T-cell lymphoma besides relapsed or refractory stage lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03439501
Study type Interventional
Source Samsung Medical Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 16, 2018
Completion date March 30, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02878278 - Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation Phase 2
Terminated NCT01948180 - Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Phase 2
Completed NCT00069238 - Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Phase 2
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Terminated NCT02359162 - Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage Phase 3
Recruiting NCT02080234 - Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL Phase 2
Completed NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Phase 1
Not yet recruiting NCT03051555 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma N/A
Not yet recruiting NCT03051542 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma N/A
Recruiting NCT03154918 - GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma Phase 2
Recruiting NCT01933282 - MESA Treatment for NK/T Cell Lymphoma Phase 2
Terminated NCT02533323 - P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens Phase 2
Recruiting NCT04417166 - Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma Phase 2
Recruiting NCT02859402 - Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Phase 2